氨甲环酸在全髋关节置换术中的疗效:一项网络Meta分析
该网络Meta分析纳入34篇文献,评估氨甲环酸(TXA)在初次全髋关节置换术(THA)中的疗效。局部、静脉和口服TXA相比安慰剂均减少失血和输血风险,但无一种剂型明显更优;重复剂量、更高剂量或给药时机变化未显著减少失血或输血风险。强证据支持TXA用于减少初次THA后失血和输血风险,但无特定给药途径、剂量、方案或时机具有明显更优的血液保护特性。
要点
- 局部、静脉和口服TXA相比安慰剂均减少失血和输血风险,但无剂型明显更优。
- 重复剂量、更高剂量或给药时机变化未显著减少失血或输血风险。
- 强证据支持TXA用于减少初次THA后失血和输血风险。
核心结论
- 强证据支持使用TXA减少初次全髋关节置换术后的失血和输血风险。
- 没有特定的给药途径、剂量、给药方案或给药时间提供明显更优的血液保护特性。
研究设计与样本
- 研究为网络Meta分析,检索Ovid-MEDLINE、Embase、Cochrane Reviews、Scopus和Web of Science数据库,纳入2017年7月之前关于初次全髋关节置换术中TXA的所有出版物。
- 对全部纳入研究完成定性和定量同质性检验,采用网络Meta分析进行直接和间接比较,并对结果进行一致性检验。
主要发现
- 局部、静脉和口服TXA制剂相比安慰剂均减少失血和输血风险,但无一种制剂明显更优。
- 使用重复剂量、更高剂量或改变给药时间未显著减少失血或输血风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tranexamic acid (TXA) is an antifibrinolytic agent commonly used to reduce blood loss in total hip arthroplasty (THA). The purpose of our study was to evaluate the efficacy of TXA in primary THA to support the combined clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Academy of Orthopaedic Surgeons, Hip Society, Knee Society, and American Society of Regional Anesthesia and Pain Medicine on the use of TXA in primary total joint arthroplasty. METHODS: A search was performed using Ovid-MEDLINE, Embase, Cochrane Reviews, Scopus, and Web of Science databases to identify all publications before July 2017 on TXA in primary THA. We completed qualitative and quantitative homogeneity testing of all included studies. Direct and indirect comparisons were analyzed using a network meta-analysis followed by consistency testing of the results. RESULTS: Two thousand one hundred thirteen publications underwent critical appraisal with 34 publications identified as representing the best available evidence for inclusion in the analysis. Topical, intravenous, and oral TXA formulations provided reduced blood loss and risk of transfusion compared to placebo, but no formulation was clearly superior. Use of repeat doses, higher doses, or variation in timing of administration did not significantly reduce blood loss or risk of transfusion. CONCLUSIONS: Strong evidence supports the use of TXA to reduce blood loss and risk of transfusion after primary THA. No specific routes of administration, dosage, dosing regimen, or time of administration provides clearly superior blood-sparing properties.
引用
- Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The Efficacy of Tranexamic Acid in Total Hip Arthroplasty: A Network Meta-analysis. J Arthroplasty. 2018. PMID: 30007789. doi:10.1016/j.arth.2018.06.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。